2-(4-(pyridin-4-yl)piperazin-1-yl)ethanamine | 30198-93-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(4-(pyridin-4-yl)piperazin-1-yl)ethanamine
• 英文别名: 2-(4-pyridin-4-yl-piperazin-1-yl)-ethylamine；2-[4-(4-Pyridinyl)piperazino]ethylamine；2-(4-pyridin-4-ylpiperazin-1-yl)ethanamine
• CAS: 30198-93-7
• 化学式: C₁₁H₁₈N₄
• 分子量: 206.291
• InChiKey: JYQXMQBFAUXDOF-UHFFFAOYSA-N

物化性质

• 沸点：
  358.0±37.0 °C(Predicted)
• 密度：
  1.101±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  45.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-(pyridin-4-yl)piperazin-1-yl)ethanamine 、 5-oxo-2,4,5,6-tetrahydro-1H-thiopyrano[3,4-c]quinoline-9-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 、 1,4-二氧六环 、 水 为溶剂， 以20%的产率得到5-oxo-N-[2-[4-(pyridin-4-yl)piperazin-1-yl]ethyl]-2,4,5,6-tetrahydro-1H-thiopyrano[3,4-c]quinoline-9-carboxamide hydrochloride
  参考文献：
  名称：

  聚吡咯并[3,4-c]喹啉-9-羧酰胺衍生物作为聚（ADP-核糖）聚合酶-1（PARP-1）抑制剂的合成和评价

  摘要：

  一系列聚（ADP-核糖）聚合酶-1（PARP-1）抑制剂，5-氧代-2,4,5,6-四氢-1 H-硫代吡喃并[3,4- c ]喹啉-9-羧酰胺衍生物，成功合成，并评估其对PARP-1的抑制活性。这些化合物是由羧酸7和适当的胺制备的，发现许多合成的化合物都具有明显的PARP-1活性。其中，9m在PARP-1酶促测定和基于细胞的测定中显示出有效的活性（IC 50  = 0.045μM，ED 50  = 0.54μM）。分子模型研究证实了所获得的生物学结果。

  DOI：

  10.1007/s00044-011-9673-6
• 作为产物：
  描述：

  2-(4-(pyridin-4-yl)piperazin-1-yl)acetonitrile 在 氢气 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以93%的产率得到2-(4-(pyridin-4-yl)piperazin-1-yl)ethanamine
  参考文献：
  名称：

  Further delineation of hydrophobic binding sites in dopamine D2/D3 receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol

  摘要：

  Here we report a structure-activity relationship (SAR) study of analogues of 5/7-{[2-(4-aryl-piperazin-1-yl)- ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol. Our SAR is focused on introduction of various substitutions in the piperazine ring of the hybrid template. The goal behind this study is to delineate the nature of the binding pocket for N-aryl substitution in the piperazine ring by observing the effect of various hydrophobic and other heteroaromatic substitutions on binding affinity (K-i), as measured with tritiated spiperone and HEK-293 cells expressing either D-2 or D-3 receptors. Functional activity of selected compounds was assessed with the GTP gamma S binding assay. Compound 8d was the most selective for the D-3 receptor in the spiperone binding assay. An interesting similarity in binding affinity was observed between isoquinoline derivative D-301 and the 2-substituted pyridine derivative 8d, suggesting the importance of relative spatial relationships between the N-atom of the ligand and the molecular determinants of the binding pocket in D-2/D-3 receptors. Functional activity assays demonstrated high potency and selectivity of (+)-8a and (-)-28b (D-2/D-3 (ratio of EC50): 105 and 202, respectively) for the D-3 receptor and both compounds were more selective compared to the reference drug ropinirole (D-2/D-3 (ratio of EC50): 29.5). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.025

文献信息

• Small-Molecule Inhibition of the UNC119-Cargo Interaction
  作者：Tom Mejuch、Guillaume Garivet、Walter Hofer、Nadine Kaiser、Eyad K. Fansa、Christiane Ehrt、Oliver Koch、Matthias Baumann、Slava Ziegler、Alfred Wittinghofer、Herbert Waldmann

  DOI：10.1002/anie.201701905

  日期：2017.5.22

  chaperones UNC119A/B regulate the cellular distribution and signaling of N-myristoylated proteins. Selective small-molecule modulators of the UNC119-cargo interaction would be invaluable tools, but have not been reported yet. We herein report the development of the first UNC119-cargo interaction inhibitor, squarunkin A. Squarunkin A selectively inhibits the binding of a myristoylated peptide representing

  N-末端肉豆蔻酰化促进膜的结合和蛋白质（特别是Src家族激酶）的活性，但是其潜在机制才刚刚被人们理解。伴侣UNC119A / B调节N-肉豆蔻酰化蛋白的细胞分布和信号传导。UNC119-货物相互作用的选择性小分子调节剂将是无价的工具，但尚未有报道。我们在此报告了第一个UNC119-货物相互作用抑制剂squarunkin A的开发。SquarunkinA用IC 50选择性抑制代表Src激酶N端的肉豆蔻酰化肽与UNC119A的结合值为10 nm。它与细胞裂解物中的UNC119蛋白结合，并干扰Src激酶的激活。我们的研究结果表明，对UNC119-货物相互作用的小分子抑制可能为调节Src激酶的活性提供新的机会，而Src激酶的活性与直接抑制酶激酶的活性无关。
• [EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ELAN PHARM INC

  公开号：WO2004098589A1

  公开（公告）日：2004-11-18

  Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  公开的是化合物I和II的结构式，它们是激肽酶B1受体拮抗剂，适用于治疗哺乳动物中由激肽酶B1受体介导的疾病，或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计还将表现出延长作用的特性。
• Novel compounds useful for bradykinin B1 receptor antagonism
  申请人：Ye Michael Xiaocong

  公开号：US20070032475A1

  公开（公告）日：2007-02-08

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor.

  揭示了一种化合物，它们是布雷金肽B1受体拮抗剂，可用于治疗或缓解由布雷金肽B1受体介导的哺乳动物疾病，或与疾病状况相关的不良症状。
• NOVEL COMPOUNDS
  申请人：Hauel Norbert

  公开号：US20110294775A1

  公开（公告）日：2011-12-01

  Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumour pain and headache diseases. The following is exemplary:

  新颖的化合物，可用于治疗急性疼痛、内脏疼痛、神经痛、炎症/疼痛受体介导的疼痛、肿瘤疼痛和头痛疾病。以下是示例：
• Substituted isoindoles and the e use thereof
  申请人：——

  公开号：US20040215019A1

  公开（公告）日：2004-10-28

  The invention relates to coagulation of the blood. Disclosed are novel compounds of formula (I), 1 a method for the production of these compounds, pharmaceutical compositions containing them, and methods of using them for the prevention and/or treatment of various diseases.

  本发明涉及血液凝固。公开了一种新的化合物(I)的公式，一种制备这些化合物的方法，含有它们的制药组合物以及使用它们预防和/或治疗各种疾病的方法。